Nimodipine is a dihydropyridine calcium channel blocker with relative selectivity for cerebral vasculature, used to reduce the incidence and severity of vasospasm-related ischaemic deficits following aneurysmal subarachnoid haemorrhage. Its narrow neurological indication demands tight control over related substances and degradation products. Simson Pharma supplies a Nimodipine reference standard alongside its known impurities for IP/BP/USP/EP-aligned testing.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Nimodipine Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.